. 2017 Jun 30;35(2):144–152. doi: 10.3857/roj.2017.00213

Table 4.

Response (%) to radiation therapy (n = 94 by site)^a)

	BED ≥ 50 Gy		BED < 50 Gy
	In-field tumor response to RT		In-field tumor response to RT
	Best^b)	Final^c)	Best^b)	Final^c)
Median RECIST
LN	-70 (PR)	-70 (PR)	-56 (PR)	-52 (PR)
Brain	-45 (PR)	-45 (PR)	-40 (PR)	100 (PD)
Bone	-2 (SD)	42 (PD)	2 (SD)	66 (PD)
Pelvic cavity	-54 (PR)	-16 (SD)	-48 (PR)	100 (PD)
Chest wall	NE	NE	NA	NA

BED, biologically effective dose; RT, radiotherapy; RECIST, Response Evaluation Criteria in Solid Tumors; LN, lymph node; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; NA, not applicable.

^a)

Each cumulative site counted separately for patients that received multiple courses of irradiation.

^b)

Percentage change of tumor from baseline.

^c)

Percentage change of tumor from nadir.